Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma
Top Cited Papers
Open Access
- 20 July 2007
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (21), 3109-3115
- https://doi.org/10.1200/jco.2006.10.2434
Abstract
Purpose: To evaluate the activity and safety of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in persistent, progressive, or recurrent mycosis fungoides or Sézary syndrome (MF/SS) cutaneous t-cell lymphoma (CTCL) subtypes. Patients and Methods: Patients with stage IB-IVA MF/SS were treated with 400 mg of oral vorinostat daily until disease progression or intolerable toxicity in this open-label phase IIb trial ( NCT00091559 ). Patients must have received at least two prior systemic therapies at least one of which included bexarotene unless intolerable. The primary end point was the objective response rate (ORR) measured by the modified severity weighted assessment tool and secondary end points were time to response (TTR), time to progression (TTP), duration of response (DOR), and pruritus relief (≥ 3-point improvement on a 10-point visual analog scale). Safety and tolerability were also evaluated. Results: Seventy-four patients were enrolled, including 61 with at least stage IIB disease. The ORR was 29.7% overall; 29.5% in stage IIB or higher patients. Median TTR in stage IIB or higher patients was 56 days. Median DOR was not reached but estimated to be ≥ 185 days (34+ to 441+). Median TTP was 4.9 months overall, and ≥ 9.8 months for stage IIB or higher responders. Overall, 32% of patients had pruritus relief. The most common drug-related adverse experiences (AE) were diarrhea (49%), fatigue (46%), nausea (43%), and anorexia (26%); most were grade 2 or lower but those grade 3 or higher included fatigue (5%), pulmonary embolism (5%), thrombocytopenia (5%), and nausea (4%). Eleven patients required dose modification and nine discontinued due to AE. Conclusion: Oral vorinostat was effective in treatment refractory MF/SS with an acceptable safety profile.Keywords
This publication has 20 references indexed in Scilit:
- Selective Induction of Apoptosis by Histone Deacetylase Inhibitor SAHA in Cutaneous T-Cell Lymphoma Cells: Relevance to Mechanism of Therapeutic ActionJournal of Investigative Dermatology, 2005
- Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced CancerJournal of Clinical Oncology, 2005
- Developing new drugs for the treatment of lymphomaEuropean Journal of Haematology, 2005
- WHO-EORTC classification for cutaneous lymphomasBlood, 2005
- Long-term Outcome of 525 Patients With Mycosis Fungoides and Sézary SyndromeArchives of Dermatology, 2003
- Update on erythrodermic cutaneous T-cell lymphoma: Report of the international society for cutaneous lymphomasJournal of the American Academy of Dermatology, 2002
- Histone deacetylases and cancer: causes and therapiesNature Reviews Cancer, 2001
- Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemiaJCI Insight, 2001
- Histone acetylation and diseaseCellular and Molecular Life Sciences, 2001
- Clinical Characteristics and Outcome of Patients With Extracutaneous Mycosis FungoidesJournal of Clinical Oncology, 2001